Tianda Pharmaceuticals Limited (HKG:0455)
Hong Kong
· Delayed Price · Currency is HKD 0.0990
-0.0020 (-1.98%)
At close: Mar 10, 2026
Tianda Pharmaceuticals Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 310.5 | 329.94 | 532.09 | 546.69 | 509.96 | 474.33 | Upgrade
|
| Revenue Growth (YoY) | -19.28% | -37.99% | -2.67% | 7.20% | 7.51% | -3.49% | Upgrade
|
| Cost of Revenue | 177.74 | 177.91 | 276.56 | 295.17 | 268.73 | 215.34 | Upgrade
|
| Gross Profit | 132.76 | 152.02 | 255.53 | 251.52 | 241.22 | 258.99 | Upgrade
|
| Selling, General & Admin | 181.87 | 192.89 | 271.45 | 285.52 | 269.46 | 281.52 | Upgrade
|
| Research & Development | 12.15 | 13.28 | 13.11 | 36.15 | 15.86 | 11.83 | Upgrade
|
| Operating Expenses | 194.02 | 206.17 | 284.56 | 321.67 | 285.32 | 293.35 | Upgrade
|
| Operating Income | -61.26 | -54.15 | -29.02 | -70.14 | -44.1 | -34.36 | Upgrade
|
| Interest Expense | -4.25 | -4.85 | -4.95 | -6.72 | -0.73 | -0.57 | Upgrade
|
| Interest & Investment Income | 0.57 | 1.1 | 3.03 | 4.34 | 2.3 | 3.23 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | -0.11 | 0.48 | -0.21 | 1.07 | -0.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.63 | 4.48 | 4.91 | 6.93 | 2.32 | 3.51 | Upgrade
|
| EBT Excluding Unusual Items | -61.25 | -53.54 | -25.55 | -65.8 | -39.13 | -28.68 | Upgrade
|
| Impairment of Goodwill | -1.34 | -1.34 | - | - | -1.58 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.02 | 0.64 | -0.29 | 0.7 | 0.67 | 1.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.2 | -0.1 | 0.14 | 1.25 | 12.03 | -0.07 | Upgrade
|
| Other Unusual Items | -0.26 | - | - | - | - | 0.05 | Upgrade
|
| Pretax Income | -63.07 | -54.34 | -25.69 | -63.85 | -28.02 | -27.44 | Upgrade
|
| Income Tax Expense | 4.62 | 7.07 | -0.69 | -4.86 | -6.34 | -1.52 | Upgrade
|
| Earnings From Continuing Operations | -67.69 | -61.41 | -25.01 | -58.99 | -21.68 | -25.92 | Upgrade
|
| Minority Interest in Earnings | 0.32 | 0.04 | 0.85 | 4.35 | 1.9 | -1.22 | Upgrade
|
| Net Income | -67.37 | -61.37 | -24.16 | -54.64 | -19.77 | -27.14 | Upgrade
|
| Net Income to Common | -67.37 | -61.37 | -24.16 | -54.64 | -19.77 | -27.14 | Upgrade
|
| Shares Outstanding (Basic) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | Upgrade
|
| Shares Outstanding (Diluted) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | Upgrade
|
| EPS (Basic) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | 23.12 | -30.3 | -99.04 | 68.63 | -61.98 | -183.32 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | -0.01 | -0.05 | 0.03 | -0.03 | -0.09 | Upgrade
|
| Dividend Per Share | - | - | 0.003 | 0.003 | 0.003 | 0.003 | Upgrade
|
| Dividend Growth | - | - | -25.01% | 33.35% | - | 100.00% | Upgrade
|
| Gross Margin | 42.76% | 46.08% | 48.02% | 46.01% | 47.30% | 54.60% | Upgrade
|
| Operating Margin | -19.73% | -16.41% | -5.46% | -12.83% | -8.65% | -7.24% | Upgrade
|
| Profit Margin | -21.70% | -18.60% | -4.54% | -9.99% | -3.88% | -5.72% | Upgrade
|
| Free Cash Flow Margin | 7.45% | -9.18% | -18.61% | 12.55% | -12.16% | -38.65% | Upgrade
|
| EBITDA | -30.87 | -24.47 | -0.95 | -27.88 | -29.64 | -20.84 | Upgrade
|
| EBITDA Margin | -9.94% | -7.42% | -0.18% | -5.10% | -5.81% | -4.39% | Upgrade
|
| D&A For EBITDA | 30.39 | 29.68 | 28.07 | 42.26 | 14.46 | 13.53 | Upgrade
|
| EBIT | -61.26 | -54.15 | -29.02 | -70.14 | -44.1 | -34.36 | Upgrade
|
| EBIT Margin | -19.73% | -16.41% | -5.45% | -12.83% | -8.65% | -7.24% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.